Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost

Maria Leon-Camarena, Leah Philips, Joseph Rimando, Colin Vale, Anthony Hunter, Michael Hochman, Amelia Langston, William Blum, Edmund Waller

Blood (2025) 146 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2025-6394

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

Interferon therapy achieves potent reduction in JAK2 allele burden in patients with myeloproliferative neoplasms: A real-world analysis

Rachel Lazris, Laneisha Maldonado Jaime, Nikolaos Papadantonakis, Michael Hochman, Colin Vale, David Frank, Anthony Hunter

Blood (2025) 146 (Supplement 1): 7344.

https://doi.org/10.1182/blood-2025-7344

Published: 2025

Journal Articles

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Nana Adjoa Ben-Crentsil, Somedeb Ball, Hannah Newman, Christopher Ryder, Surendra Neupane, Anthony Hunter, Yu-Hung Wang, Kiran Batta, Kristian Gurashi, Traci Kruer, Maria Balasis, Ariel Quintana, Rami Komrokji, David Sallman, Andrew Kuykendall, Tracy George, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2025-3763

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Blood (2025) 146 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2025-3775

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell

Blood (2025) 146 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2025-2707

Published: 2025

Journal Articles

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2025-5118

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Blood (2022) 140 (Supplement 1): 9824–9827.

https://doi.org/10.1182/blood-2022-164816

Published: 2022

Journal Articles

Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia

Connor M. Walsh, Anthony Hunter, Terra Lasho, Christy Finke, Rami S. Komrokji, Mithun V. Shah, Ayalew Tefferi, Abhishek A. Mangaonkar, Matthew T Howard, Naseema Gangat, Aref Al-Kali, Najla Al Ali, Eric Padron, Mrinal M. Patnaik

Blood (2021) 138 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2021-150786

Published: 2021

Journal Articles

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Andrew T Kuykendall, MD, Anthony Hunter, MD, Ling Zhang, MD, Eric Padron, MD, Chetasi Talati, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 2956.

https://doi.org/10.1182/blood-2019-130661

Published: 2019

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

Leukocytosis Is Associated with End Organ Damage in Chronic Myelomonocytic Leukemia (CMML) and Can be Mitigated with Cytoreductive Therapy

Anthony Hunter, MD, Najla Al Ali, M.Sc, Anne Mai, Chetasi Talati, MD, Andrew Kuykendall, MD, Kendra L. Sweet, MD, David A Sallman, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2018) 132 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2018-99-120184

Published: 2018

Journal Articles

Hemgolobin S-C Disease at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Anthony Hunter, MD, Ross M. Fasano, MD, James R. Eckman, MD, Morgan L. McLemore, MD, Fuad El Rassi, MD

Blood (2016) 128 (22): 4873.

https://doi.org/10.1182/blood.V128.22.4873.4873

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Interferon therapy achieves potent reduction in JAK2 allele burden in patients with myeloproliferative neoplasms: A real-world analysis

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Leukocytosis Is Associated with End Organ Damage in Chronic Myelomonocytic Leukemia (CMML) and Can be Mitigated with Cytoreductive Therapy

Hemgolobin S-C Disease at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only